Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg provides relief for multiple pain-related symptoms by combining two powerful ingredients indicated for OTC pain relief, ibuprofen and acetaminophen. Ibuprofen works through the body targeting pain at the source while Acetaminophen blocks pain signal to the brain.

The innovation takes these two powerful pain fighting ingredients and combines them into one tablet to offer fast, strong pain relief. The company plans to launch the product immediately.

Mark Saldanha, managing director of the company said, “We are committed to expanding our portfolio in aTe Pain Management, this approval further demonstrates our regulatory and manufacturing capabilities and our strength to follow a focused growth approach. We will continue to work diligently towards sustaining this momentum in the coming quarters.”

Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations.

The company's consolidated net profit zoomed 191.46% to Rs 81.93 crore in Q4 FY23 as against Rs 28.11 crore recorded in Q4 FY22. Revenue from operations rose 16.25% year on year to Rs 485.98 crore in the quarter ended 31 March 2023.

The scrip hits 52 week high at Rs 102.90 in intraday today.